Skip to main content
NCBI home page
Cytotechnology logoLink to Cytotechnology
. 2002 Jul;39(2):91–116. doi: 10.1023/A:1022969101804

Virus contaminations of cell cultures – A biotechnological view

O-W Merten 1
PMCID: PMC3463984  PMID: 19003296

Abstract

In contrast to contamination by microbes and mycoplasma, which can be relatively easily detected, viral contamination present a serious threat because of the difficulty in detecting some viruses and the lack of effective methods of treating infected cell cultures. While some viruses are capable of causing morphological changes to infected cells (e.g. cytopathic effect)which are detectable by microscopy some viral contaminations result in the integration of the viral genome as provirus, this causes no visual evidence, by means of modification of the cellular morphology. Virus production from such cell lines, are potentially dangerous for other cell cultures (in research labs)by cross contaminations, or for operators and patients (in the case of the production of injectable biologicals) because of potential infection. The only way to keep cell cultures for research, development, and the biotech industry virus-free is the prevention of such contaminations. Cell cultures can become contaminated by the following means: firstly, they may already be contaminated as primary cultures (because the source of the cells was already infected), secondly, they were contaminated due to the use of contaminated raw materials, or thirdly, they were contaminated via an animal passage. This overview describes the problems and risks associated with viral contaminations in animal cell culture, describes the origins of these contaminations as well as the most important virsuses associated with viral contaminations in cell culture. In addition, ways to prevent viral contaminations as well as measures undertaken to avoid and assess risks for viral contaminations as performed in the biotech industry are briefly described.

Keywords: animal cell culture, CHO, continuous cell lines, hybridoma, prevention, primary cells, raw materials, risks, viral contaminants

Full Text

The Full Text of this article is available as a PDF (280.8 KB).

References

  1. Adamson SR. Experiences of virus, retrovirus and retroviruslike particles in chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Dev Biol Standard. 1998;93:89–96. [PubMed] [Google Scholar]
  2. Anderson KP, Lie YS, Low M-AL, Williams SR, Fennie EH, Nguyen TP, Wurm FM. Presence and transcription of intracisternal A-particle related sequences in CHO cells. J Virol. 1990;64:2021–2032. doi: 10.1128/jvi.64.5.2021-2032.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aranha-Creado H, Oshima K, Jafari S, Howard G, Jr, Brandwein H. Virus retention by a hydrophilic triple-layer PVDF microporous membrane filter. PDA J Pharm Sci Technol. 1997;51:119–124. [PubMed] [Google Scholar]
  4. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology. 1975;68:556–560. doi: 10.1016/0042-6822(75)90298-6. [DOI] [PubMed] [Google Scholar]
  5. Berthold W, Werz W, Walter JK. Relationship between nature and source of risk and process validation. Dev Biol Standard. 1996;88:59–71. [PubMed] [Google Scholar]
  6. Bhatt PN, Jacoby RO, Barthold SW. Contamination of transplanatble murine tumors with lymphocytic choriomeningitis virus. Lab Anim Sci. 1986;36:136–139. [PubMed] [Google Scholar]
  7. Biagini P, Gallian P, Touinssi M, Cantaloube JF, Zapitelli J, De Lamballerie X, De Micco P. High prevalence of TT virus infection in French blood donors revealed by the use of three PCR systems. Transfusion. 2000;40:590–595. doi: 10.1046/j.1537-2995.2000.40050590.x. [DOI] [PubMed] [Google Scholar]
  8. Bolin SR, Matthews PJ, Ridpath JF. Methods for detection and frequency of contamination of fetal calf serum with bovine viral diaahea virus and antibodies against bovine viral diarrhea virus. J Vet Diagn Invest. 1991;3:199–203. doi: 10.1177/104063879100300302. [DOI] [PubMed] [Google Scholar]
  9. Bolin SR, Ridpath JF, Black J, Macy M, Roblin R. Survey of cell lines in the American Type Culture Collection for bovine viral diarrhea virus. J Virol Meth. 1994;48:211–221. doi: 10.1016/0166-0934(94)90120-1. [DOI] [PubMed] [Google Scholar]
  10. Brands R, Visser J, Medema J, Palache AM, Van Scharrenburg GJM. InfluvacTC: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Standard. 1999;98:93–100. [PubMed] [Google Scholar]
  11. Brown F, Meyer RF, Law M, Kramer E, Newman JFE. A universal virus inactivant for decontaminating blood and biopharmaceutical products. Dev Biol Standard. 1999;99:119–130. [PubMed] [Google Scholar]
  12. Buller RML, Weinblatt AC, Hamburger AW, Wallace GD. Observations on the replication of ectromelia virus in mousederived cell lines: Implications for emidemiology of mousepox. Lab Anim Sci. 1987;37:28–32. [PubMed] [Google Scholar]
  13. Burstyn DG. Contamination of genetically engineered chinese hamster ovary cells. Dev Biol Standard. 1996;88:199–203. [PubMed] [Google Scholar]
  14. Butler M. The characteristics and growth of cultured cells. In: Butler M, editor. Mammalian Cell Biotechnology - A Practical Approach. Oxford, U.K.: IRL Press/Oxford University Press; 1991. pp. 1–25. [Google Scholar]
  15. Cartwright T. Animal Cells as Bioreactors. Cambridge Studies in Biotechnology. Cambridge, U.K.: Cambridge University Press; 1994. [Google Scholar]
  16. Collins MJ, Jr, Parker JC. Murine virus contaminants of leukemia viruses and transplantable tumors. J Natl Cancer Inst. 1972;49:1139–1143. [PubMed] [Google Scholar]
  17. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/PharmacyWorking Party on Safety Medicines. EEC Regulatory Document. Note for Guidance Guidelines for medicinal products derived from human blood and plasma. Biologicals. 1992;20:159–164. doi: 10.1016/S1045-1056(05)80064-8. [DOI] [PubMed] [Google Scholar]
  18. CPMP (2002) Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products. EMEA, 25 April 2002, CPMP/BWP/1793/02.
  19. Crawford DH, Achong BG, Teich NM, Finerty S, Thompson JL, Epstein MA, Giovanella BC. Identification of murine endogenous xenotropic retrovirus in cultured multicellular tumour spheroids from nude-mouse-passaged nasopharyngeal carcinoma. Int J Cancer. 1979;23:1–7. doi: 10.1002/ijc.2910230102. [DOI] [PubMed] [Google Scholar]
  20. Croghan DL, Matchett A, Koski TA. Isolation of porcine parvovirus from commercial trypsin. Appl Microbiol. 1973;26:431–433. doi: 10.1128/am.26.3.431-433.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dinowitz M, Lie YS, Low M-AL, Lazar R, Fautz C, Potts B, Sernatinger J, Anderson K. Recent studies on retrovirus-like particles in chinese hamster ovary cells. Dev Biol Standard. 1992;76:201–207. [PubMed] [Google Scholar]
  22. Eddy BE, Borman GS, Berkeley WH, Young RD. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med. 1961;197:191–197. doi: 10.3181/00379727-107-26576. [DOI] [PubMed] [Google Scholar]
  23. Ellis JA, Konoby C, West KH, Allan GM, Krakowka S, McNeilly F, Meehan B, Walker I. Lack of antibodies to porcine circovirus type 2 virus in beef and dairy cattle and horses in western Canada. Can Vet J. 2001;42:461–464. [PMC free article] [PubMed] [Google Scholar]
  24. Eloit M. Risques virologiques associés aux matières premières extraites de tissus animaux utilisées dans la fabrication des médicaments. Virologie. 1997;1:413–422. [Google Scholar]
  25. Eloit M. Risks of virus transmission associated with animal sera or substitutes and methods of control. Dev Biol Standard. 1999;99:9–16. [PubMed] [Google Scholar]
  26. Enders JF, Weller TH, Robbins FC. Cultivation of Lansing strain of poliomyelitis virus in culture of various human embryonic tissues. Science. 1949;109:85–87. doi: 10.1126/science.109.2822.85. [DOI] [PubMed] [Google Scholar]
  27. Erickson GA, Landgraf JG, Wessman SJ, Koski TA, Moss LM. Detection and elimination of adventitious agents in continuous cell lines. Dev Biol Standard. 1989;70:59–66. [PubMed] [Google Scholar]
  28. Falcone E, Tollis M, Conti G. Bovine viral diarrhea disease associated with a contaminated vaccine. Vaccine. 2000;18:387–388. doi: 10.1016/s0264-410x(99)00244-3. [DOI] [PubMed] [Google Scholar]
  29. Fikrig MK, Tattersall P. Latent parvoviral infection of continuous cell lines. Dev Biol Standard. 1992;76:285–293. [PubMed] [Google Scholar]
  30. French GR, Foulke RS, Brand OD, Addy GA, Lee HW, Lee PW. Korean haemorrhagic fever. Propagation of the etiologic agent in a cell line of human origin. Science. 1981;211:1046–1048. doi: 10.1126/science.6110243. [DOI] [PubMed] [Google Scholar]
  31. Fritsch E. Validation of virus removal in large scale purification processes. Dev Biol Standard. 1992;76:239–248. [PubMed] [Google Scholar]
  32. Froud SJ, Birch J, McLean C, Shepherd AJ, Smith KT, et al. Viral contaminants found in mouse cell lines used in the production of biological products. In: Carrondo MJT, et al., editors. Animal Cell Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1997. [Google Scholar]
  33. Garnick RL. Experience with viral contamination in cell culture. Dev Biol Standard. 1996;88:49–56. [PubMed] [Google Scholar]
  34. Graf E-G, Jander E, West A, Pora H, Aranha-Creado H. Virus removal by filtration. Dev Biol Standard. 1999;99:89–94. [PubMed] [Google Scholar]
  35. Hallauer C, Kronauer G. Nachweis von Gelbfiebervirus-Haemagglutinin in Menschlichen Explantaten. Arch ges Virusf. 1960;10:267–287. doi: 10.1007/BF01268045. [DOI] [PubMed] [Google Scholar]
  36. Hallauer C, Kronauer G, Siegl G. Parvoviruses as contaminants of permanent human cell lines. I. Virus isolations from 1960-1970. Arch ges Virusf. 1971;35:80–90. doi: 10.1007/BF01249755. [DOI] [PubMed] [Google Scholar]
  37. Hansen G, Foster L. Viral safety in serum for cell culture use. Art to Science. 1997;16:1–7. [Google Scholar]
  38. Harasawa R. Adventitious pestivirus RNA in live virus vaccines against bovine and swine diseases. Vaccine. 1995;13:100–103. doi: 10.1016/0264-410X(95)80018-9. [DOI] [PubMed] [Google Scholar]
  39. Harasawa R, Mizusawa H. Demonstration and genotyping of pestivirus RNA from mammalian cell lines. Microbiol Immunol. 1995;39:979–985. doi: 10.1111/j.1348-0421.1995.tb03301.x. [DOI] [PubMed] [Google Scholar]
  40. Harasawa R, Sasaki T. Sequence analysis of the 5' untranslated region of pestivirus RNA demonstrated in interferons for human use. Biologicals. 1995;23:263–269. doi: 10.1006/biol.1995.0044. [DOI] [PubMed] [Google Scholar]
  41. Hay RJ. Operator-induced contamination in cell culture systems. Dev Biol Standard. 1991;75:193–204. [PubMed] [Google Scholar]
  42. Hoggan MD. Adenovirus associated virus. Progr Med Virol. 1970;12:211–239. [PubMed] [Google Scholar]
  43. Hoggan MD, Thomas GF, Johnson FB. The Proceedings of the 4th Lepetit Colloquium. Amsterdam, The Netherlands: North Holland Publishing; 1972. Continuous 'carriage' of adenovirus-associated virus genome in cell culture in the absence of helper adenovirus; pp. 243–249. [Google Scholar]
  44. Horaud F. La sécurité virale des produits biologiques: Aspects historiques et conceptuels. Virologie. 1997;1:365–372. [Google Scholar]
  45. Hughes B (1996) Key points from Nettleton and Rweyemamu (1980): Association of calf serum with parvovirus infection. [PubMed]
  46. ICH Topic Q5A (1997) Quality of Biotechnological Products: Viral safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Note for guidance - CPMP/ICH/295/95, http://www.eudra.org/emea.html/.
  47. Jayme DW. An animal origin perspective of common constituents of serum-free medium formulations. Dev Biol Standard. 1999;99:181–187. [PubMed] [Google Scholar]
  48. Johnston A, MacGregor A, Borovec S, Hattarki M, Stuckly K, Anderson D, Goss NH, Oates A, Uren E. Inactivation and clearance of viruses during the manufacture of high purity Factor IX. Biologicals. 2000;28:129–136. doi: 10.1006/biol.1999.0242. [DOI] [PubMed] [Google Scholar]
  49. Kappler A, Lutz-Wallace C, Sapp T, Sidhu M. Detection of bovine polyomavirus contamination in fetal bovine sera and modified live viral vaccines using polemerase chain reaction. Biologicals. 1996;24:131–135. doi: 10.1006/biol.1996.0017. [DOI] [PubMed] [Google Scholar]
  50. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F. Development of a Vero cell derived influenza whole virus vaccine. Dev Biol Standard. 1999;98:101–110. [PubMed] [Google Scholar]
  51. Klein G, Dombos L, Gathoskar B. Sensitivity of Epstein-Barr virus producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer. 1972;10:44–57. doi: 10.1002/ijc.2910100108. [DOI] [PubMed] [Google Scholar]
  52. Kniazeff AJ. Endogenous virus contaminants in fetal bovine serum and their role in tissue culture contamination. In: Fogh J, editor. Contamination in Tissue Culture. New York: Academic Press; 1973. pp. 233–242. [Google Scholar]
  53. Kreeft HAJG, Greiser-Wilke I, Moenning V, Horzinek MC. Attempts to characterize bovine viral diarrhea virus isolated from cattle after immunization with a contaminated vaccine. Dtsch Tierärztl Wschr. 1990;97:63–65. [PubMed] [Google Scholar]
  54. Kuff EL, Lueders KK. The intracisternal A-particle gene family; structure and functional aspects. Adv Cancer Res. 1988;51:183–276. doi: 10.1016/S0065-230X(08)60223-7. [DOI] [PubMed] [Google Scholar]
  55. Kurth J, Waldmann R, Heith J, Mausbach K, Burian R. Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation. Dev Biol Standard. 1999;99:111–118. [PubMed] [Google Scholar]
  56. Larzul D. Viral validation design of a manufacturing process. Dev Biol Standard. 1999;99:139–150. [PubMed] [Google Scholar]
  57. LeDuc JW, Smith GA, Macy M, Hay RJ. Certified cell lines of rat origin free of infection with Hantavirus. J Infect Dis. 1985;1522:1082–1083. doi: 10.1093/infdis/152.5.1082. [DOI] [PubMed] [Google Scholar]
  58. Leiter EH, Malinoski FJ, Eppig JJ. An epithelial cell line with chronic polyoma infection established from a spontaneous mouse pancreatic adenocarcinoma. Cancer Res. 1978;38:969–977. [PubMed] [Google Scholar]
  59. Levy JA. Mouse plasmacytoma cells produce infectious type C viruses. The Lancet. 1983;ii:522. doi: 10.1016/S0140-6736(83)90557-3. [DOI] [PubMed] [Google Scholar]
  60. Lloyd G, Jones N. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J Infect. 1986;12:117–125. doi: 10.1016/S0163-4453(86)93533-4. [DOI] [PubMed] [Google Scholar]
  61. Lubiniecky AS, Shadle PJ. Raw material considerations. Dev Biol Standard. 1997;91:65–72. [PubMed] [Google Scholar]
  62. Magrath DI. Safety of vaccines produced in continuous cell lines. Dev Biol Standard. 1991;75:17–20. [PubMed] [Google Scholar]
  63. Mahy BWJ, Dykewicz C, Fisher-Hoch S, Ostroff S, Tipple M, Sanchez A. Virus zoonosis and their potential for contamination of cell culture. Dev Biol Standard. 1991;75:183–189. [PubMed] [Google Scholar]
  64. Makoschey B, Patel JR and Van Gelder PTJA (2002) Serum-free produced bovine herpesvirus type 1 and bovine parainfluenza type 3 virus vaccines are efficacious and safe. Cytotechnology (in press). [DOI] [PMC free article] [PubMed]
  65. Mareschal J-C. Quality control of bovine serum used for vaccine production. Dev Biol Standard. 1999;99:61–68. [PubMed] [Google Scholar]
  66. Mayor HD, Melnick JL. Small deoxyribonucleic acidcontaining viruses. Nature. 1966;210:331–332. doi: 10.1038/210331a0. [DOI] [PubMed] [Google Scholar]
  67. Mayor HD, Ito M, Jordan LE, Melnick JL. Morphological studies on the replication of a defective satellite virus and its helper adenovirus. J Natl Cancer Inst. 1967;38:805–820. [PubMed] [Google Scholar]
  68. McCormick JG, Sasso DR, Palmer EL, Kiley MP. Morphological identification of the agent of Korean haemorrhagic fever (Hantaan virus) as a member of the Bunyaviridae. The Lancet. 1982;i:765–768. doi: 10.1016/S0140-6736(82)91812-8. [DOI] [PubMed] [Google Scholar]
  69. Merten O-W. Safety issues of animal products used in serumfree media. Dev Biol Standard. 1999;99:167–180. [PubMed] [Google Scholar]
  70. Minor PD. Mammalian cells and their contaminants. Dev Biol Standard. 1996;88:25–29. [PubMed] [Google Scholar]
  71. Moore WA. Experience in cell line testing. Dev Biol Standard. 1992;76:51–56. [PubMed] [Google Scholar]
  72. Nakai N, Kawaguchi C, Nawa K, Kobayashi S, Katsuta Y, Watanabe M. Detection and elimination of contaminating microorganisms in transplantable tumors and cell lines. Exp Anim. 2000;49:309–313. doi: 10.1538/expanim.49.309. [DOI] [PubMed] [Google Scholar]
  73. Nettleton PF, Rweyemamu MM. The association of calf serum with the contamination of BHK 21 clone 13 suspension cells by a parvovirus serologically related to the Minute Virus of Mice (MVM) Arch Virol. 1980;64:359–374. doi: 10.1007/BF01320621. [DOI] [PubMed] [Google Scholar]
  74. Nicklas W, Kraft V, Meyer B. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. Lab Anim Sci. 1993;43:296–299. [PubMed] [Google Scholar]
  75. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A noveal DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun. 1997;241:92–97. doi: 10.1006/bbrc.1997.7765. [DOI] [PubMed] [Google Scholar]
  76. O'Connor B, Gauvreau H, West K, Bogdan J, Ayroud M, Clark EG, Konoby C, allan G, Ellis JA. Multiple porcine circovirus 2-associated abortions and reproductive failure in a multisite swine production unit. Can Vet J. 2001;42:551–553. [PMC free article] [PubMed] [Google Scholar]
  77. Peters CJ, Jahrling PB, Ksiazek TG, Johnson ED, Lupton HW. Filovirus contamination of cell cultures. Dev Biol Standard. 1992;76:267–274. [PubMed] [Google Scholar]
  78. Plavsic MZ, Daley JP, Danner DJ, Weppner DJ. Gamma irradiation of bovine sera. Dev Biol Standard. 1999;99:95–109. [PubMed] [Google Scholar]
  79. Poiley JA. Methods for the detection of adventitious viruses in cell cultures used in the production of biotechnology products. Bioprocess Tech. 1990;10:483–494. [PubMed] [Google Scholar]
  80. Rabenau H, Ohlinger V, Anderson J, Selb B, Cinatl J, Wolf W, Frost J, Mellor P, Doerr HW. Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV) Biologicals. 1993;21:207–214. doi: 10.1006/biol.1993.1077. [DOI] [PubMed] [Google Scholar]
  81. Robertson JS. Strategy for adventitious agent assays. Dev Biol Standard. 1996;88:37–40. [PubMed] [Google Scholar]
  82. Roehe PM, Edwards S. Comparison of pestivirus multiplication in cells of different species. Res Vet Sci. 1994;57:210–214. doi: 10.1016/0034-5288(94)90059-0. [DOI] [PubMed] [Google Scholar]
  83. Schuurman R, Van Steenis B, Sol C. Review. Bovine polyomavirus, a frequent contaminant of calf serum. Biologicals. 1991;19:265–270. doi: 10.1016/S1045-1056(05)80014-4. [DOI] [PubMed] [Google Scholar]
  84. Sanchez J. R., Nauwynck HHJ, McNeilly F, Allan GM, Pensaert Porcine circovirus 2 infection in swine foetuses inoculated at different stages of getation. Vet Microbiol. 2001;83:169–176. doi: 10.1016/S0378-1135(01)00425-4. [DOI] [PubMed] [Google Scholar]
  85. Schuurman R, Van Steenis B, Van Strieben A, Van der Noordaa J, Sol C. Frequent detection of bovine polyomavirus (BPyV) in commercial batches of calf serum, using the polymerase chain reaction. J Gen Virol. 1991;72:2739–2745. doi: 10.1099/0022-1317-72-11-2739. [DOI] [PubMed] [Google Scholar]
  86. Schweizer H, Sprössig M, Mücke H, Wutzler P. Peracetic acid as sterilizing agent for culture serum. Nature New Biology. 1972;240:61–62. doi: 10.1038/240061a0. [DOI] [PubMed] [Google Scholar]
  87. Shah K, Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol. 1976;103:1–12. doi: 10.1093/oxfordjournals.aje.a112197. [DOI] [PubMed] [Google Scholar]
  88. Shah KV, Willard S, Myers RE, Hess DM, DiGiacomo R. Experimental infection of rhesus with Simian Virus 40 (SV40) Proc Soc Exp Biol Med. 1969;130:196–203. doi: 10.3181/00379727-130-33520. [DOI] [PubMed] [Google Scholar]
  89. Smith CEG, Simpson DIH, Bowen E., Zlotnik I. Fatal human disease from Vervet monkeys. The Lancet. 1967;ii:1119–1121. doi: 10.1016/s0140-6736(67)90621-6. [DOI] [PubMed] [Google Scholar]
  90. Spriggs DR, Krueger RG. Identification of the major structural proteins of two BALB/c myeloma C-type viruses. Virology. 1979;98:35–44. doi: 10.1016/0042-6822(79)90522-1. [DOI] [PubMed] [Google Scholar]
  91. Sprössig M, Mücke H. Ñber die antimikrobielle Wirkung der Peressigsäure. 5. Mitteilung: Untersuchung zur viruziden Wirkung. Pharmazie. 1967;23:665–667. [PubMed] [Google Scholar]
  92. Stones PB. Production and control of live oral poliovirus vaccine in WI-38 human diploid cells. Dev Biol Standard. 1977;37:251–253. [PubMed] [Google Scholar]
  93. Sweet BH, Hilleman MR. The vacuolating virus, S.V.40. Proc Soc Exp Biol Med. 1960;105:420–427. doi: 10.3181/00379727-105-26128. [DOI] [PubMed] [Google Scholar]
  94. Tischer I, Gelderblom H, Vettermann W, Kock MA. A very small porcine virus with circular single-stranded DNA. Nature. 1982;295:64–66. doi: 10.1038/295064a0. [DOI] [PubMed] [Google Scholar]
  95. Troccoli NM, McIver J, Losikoff A, Poiley J. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals. 1998;26:321–329. doi: 10.1006/biol.1998.0164. [DOI] [PubMed] [Google Scholar]
  96. Van der Noordaa S. C., Schuurman R. Bovine polyomavirus, a frequent contaminant of calf sera. Dev Biol Standard. 1999;99:45–47. [PubMed] [Google Scholar]
  97. Vannier P, Leforban Y, Carnero R, Cariolet R. Contamination of a live virus vaccine against pseudorabies (Aujeszky's Disease) by an ovine pestivirus pathogen for the pig. Ann Rech Vét. 1988;19:283–290. [PubMed] [Google Scholar]
  98. Van Steenis G, Van Wezel AL, De Groot IGM, Kruijt BC. Use of captive-bred monkeys for vaccine production. Dev Biol Standard. 1980;45:99–105. [PubMed] [Google Scholar]
  99. VanWezel AL, Van der Velden-de Groot CAM, Van Herwaarden JAM. The production of inactivated poliovaccine on serially cultivated kidney cells from captive-bred monkeys. Dev Biol Standard. 1980;46:151–158. [PubMed] [Google Scholar]
  100. Van Wezel AL, Van Steenis G, Hannik C., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Standard. 1978;41:159–168. [PubMed] [Google Scholar]
  101. Waldeck W, Sauer G. New oncogenic papovavirus from primate cells. Nature. 1977;269:171–173. doi: 10.1038/269171a0. [DOI] [PubMed] [Google Scholar]
  102. Weiss RA. Retroviruses produced by hybridomas. New Engl J Med. 1982;307:1587. doi: 10.1056/NEJM198212163072509. [DOI] [PubMed] [Google Scholar]
  103. Werz W, Hoffmann H, Haberer K, Walter JK. Strategies to avoid virus transmissions by biopharmaceutic products. Arch Virol. 1997;S13:245–256. doi: 10.1007/978-3-7091-6534-8_23. [DOI] [PubMed] [Google Scholar]
  104. Wessman SJ, Levings RL. Benefits and risks due to animal serum used in cell culture production. Dev Biol Standard. 1999;99:3–8. [PubMed] [Google Scholar]
  105. Wilbur LA, Evermann JF, Levings RL, Stoll IR, Starling DE, Spillers CA, Gustafson GA, McKeirnan AJ. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with bluetongue virus. JAVMA. 1994;204:1762–1765. [PubMed] [Google Scholar]
  106. Willkommen H, Scheiblauer H, Löwer J. Serum and serum substitutes: Virus safety by inactivation or removal. Dev Biol Standard. 1999;99:131–138. [PubMed] [Google Scholar]
  107. Wognum AW, Sol CJA, Van der Noordaa J, Van Steenis G, Osterhaus ADME. Isolation and characterization of a papovavirus from cynomolgus macaque kidney cells. Virology. 1984;134:254–257. doi: 10.1016/0042-6822(84)90293-9. [DOI] [PubMed] [Google Scholar]
  108. Yanagi M, Bukh J, Emerson, Purcell RH. Contamination of commercially available fetal bovine sera with bovine viral diarrhea virus genomes: Implications for the study of hepatitis C cirus in cell cultures. J Infect Dis. 1996;174:1324–1327. doi: 10.1093/infdis/174.6.1324. [DOI] [PubMed] [Google Scholar]
  109. Yuasa N, Taniguchi T, Yoshida I. Isolation and characteristics of an agent inducing anemia in chicks. Avian Dis. 1979;23:366–385. doi: 10.2307/1589567. [DOI] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES